Deutsch English Français

Contact

EP2493298

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2493298

EP2493298 - THE USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 02.09.2016 Database last updated on 05.10.2024
Most recent event Tooltip	02.09.2016	Application deemed to be withdrawn	published on 05.10.2016 [2016/40]
Applicant(s)	For all designated states Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge, MA 02139 / US
	For all designated states The General Hospital Corporation d/b/a Massachusetts General Hospital 55 Fruit Street Boston, MA 02114 / US
	For all designated states The Broad Institute, Inc. 7 Cambridge Center Cambridge, MA 02142 / US
	[N/P]
Former [2012/36]	For all designated states Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge, MA 02139 / US
	For all designated states The General Hospital Corporation d/b/a Massachusetts General Hospital 55 Fruit Street Boston, MA 02114 / US
	For all designated states The Broad Institute, Inc. 7 Cambridge Center Cambridge, MA02142 / US
Inventor(s)	01 / TSAI, Li-Huei 26 Fresh Pond Parkway Cambridge MA 02138 / US
	02 / GUAN, Ji-Song 28 Ninth Street Apt. 108 Medford MA 02155 / US
	03 / HAGGARTY, Stephen, J. 320 Savin Hill Avenue, No.4 Dorchester MA 02125 / US
	04 / HOLSON, Edward 66 Forest Street Newton Highlands MA 02461 / US
	05 / WAGNER, Florence 4 Old Country Path Ashland MA 01721 / US
	06 / GRAEFF, Johannes 89 Ridge Road Waban MA 02468 / US
	[2012/36]
Representative(s)	Potter Clarkson Chapel Quarter Mount Street Nottingham NG1 6HQ / GB
	[N/P]
Former [2013/37]	Potter Clarkson LLP The Belgrave Centre Talbot Street Nottingham NG1 5GG / GB
Former [2012/43]	Wainwright, Jane Helen, et al Potter Clarkson LLP Park View House 58 The Ropewalk Nottingham NG1 5DD / GB
Former [2012/36]	Korn, Richard Mervyn Potter Clarkson LLP Park View House 58 The Ropewalk Nottingham NG1 5DD / GB
Application number, filing date	10827583.5	29.10.2010
	WO2010US54872
Priority number, date	US20090265468P	01.12.2009 Original published format: US 265468 P
	US20090256927P	30.10.2009 Original published format: US 256927 P
	[2012/36]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2011053876
	Date:	05.05.2011
	Language:	EN
	[2011/18]
	Type:	A1 Application with search report
	No.:	EP2493298
	Date:	05.09.2012
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 05.05.2011 takes the place of the publication of the European patent application.
	[2012/36]
Search report(s)	International search report - published on:	US	05.05.2011
	(Supplementary) European search report - dispatched on:	EP	12.03.2013
Classification	IPC:	A01N37/12, A61K31/195, A61K31/167, A61K45/06, C07C237/42	[2013/14]
	CPC:	A61K31/195 (EP,US); A61K31/167 (EP,US); A61K45/06 (EP,US); A61P25/00 (EP); A61P25/14 (EP); A61P25/18 (EP); (+) A61P25/22 (EP); A61P25/28 (EP); A61P25/30 (EP); A61P43/00 (EP); C07C237/42 (EP,US) (-)
	C-Set:	A61K31/167, A61K2300/00 (EP,US)
	Former IPC [2012/36]	A01N37/12, A61K31/195
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2012/36]
Title	German:	VERWENDUNG VON CI-994 UND DINALIN ZUR BEHANDLUNG VON GEDÄCHTNIS-/KOGNITIVEN UND ANGSTSTÖRUNGEN	[2012/36]
	English:	THE USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS	[2012/36]
	French:	UTILISATION DE CI-994 ET DE DINALINE POUR LE TRAITEMENT DE TROUBLES DE LA MÉMOIRE/COGNITION ET DE L'ANXIÉTÉ	[2012/36]
Entry into regional phase	23.05.2012	National basic fee paid
	23.05.2012	Search fee paid
	23.05.2012	Designation fee(s) paid
	23.05.2012	Examination fee paid
Examination procedure	23.05.2012	Examination requested [2012/36]
	14.10.2013	Amendment by applicant (claims and/or description)
	03.04.2014	Despatch of a communication from the examining division (Time limit: M06)
	08.10.2014	Reply to a communication from the examining division
	17.02.2015	Despatch of a communication from the examining division (Time limit: M06)
	26.06.2015	Reply to a communication from the examining division
	03.05.2016	Application deemed to be withdrawn, date of legal effect [2016/40]
	31.05.2016	Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2016/40]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 03.04.2014
Fees paid	Renewal fee
	25.10.2012	Renewal fee patent year 03
	28.10.2013	Renewal fee patent year 04
	27.10.2014	Renewal fee patent year 05
	Penalty fee
	Additional fee for renewal fee
	31.10.2015	06 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]EP1591109 (G2M CANCER DRUGS AG [DE], et al) [X] 1,3,4,6,8-10 * claims 11,12,32,33 * * page 6, paragraph 33 *;
		[XI]WO2007049262 (BERAND LTD [IE], et al) [X] 1,3,4,8-10 * claims 1,11,14 * * page 10, line 8 * * page 6, line 29 - page 7, line 3 * * page 11, line 31 - page 12, line 2 * [I] 2,5,7,12-14;
		[XP]WO2010065117 (MASSACHUSETTS INST TECHNOLOGY [US], et al) [XP] 1,4,6,8,9 * page 76; figures 12,13; example 5 ** claim 1 *;
		[XI] - LANGLEY B ET AL, "REMODELING CHROMATIN AND STRESS RESISTANCE IN THE CENTRAL NERVOUS SYSTEM: HISTONE DEACETYLASE INHIBITORS AS NOVEL AND BROADLY EFFECTIVE NEUROPROTECTIVE AGENTS", CURRENT DRUG TARGETS. CNS & NEUROLOGICAL DISORDERS, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, (20050201), vol. 4, no. 1, doi:10.2174/1568007053005091, ISSN 1568-007X, pages 41 - 50, XP009048265 [X] 1,4,6,8,9 * page 43, column r, paragraph 2 - page 44, column l * * page 45, column r, paragraph 2 - page 46 * * page 45, column l, paragraph 3 * [I] 2,5,7,12-14 DOI: http://dx.doi.org/10.2174/1568007053005091
		[X] - SAMA F SLEIMAN ET AL, "Putting the 'HAT' back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions", EXPERT OPINION ON INVESTIGATIONAL DRUGS, (20090501), vol. 18, no. 5, doi:10.1517/13543780902810345, ISSN 1354-3784, pages 573 - 584, XP055054483 [X] 1,4,6,8,9 * page 5, paragraph 4 - page 9 * * page 3, paragraph 1 * DOI: http://dx.doi.org/10.1517/13543780902810345
		[X] - PAUER LYNNE R ET AL, "Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (2004), Database accession no. PREV200500090244, XP002692836 [X] 8-11 * abstract * DOI: http://dx.doi.org/10.1081/CNV-200039852
		[ ] - PAUER LYNNE R ET AL, "Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors", CANCER INVESTIGATION, (2004), vol. 22, no. 6, ISSN 0735-7907, pages 886 - 896
		[I] - PRENDERGAST A ET AL, "Treatment with histone deacetylase inhibitors SAHA and MS-275 ameliorates the core symptoms of asocialty and cognitive impairment in an animal model of autism", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, & 38TH ANNUAL MEETING OF THE SOCIETY-FOR-NEUROSCIENCE; WASHINGTON, DC, USA; NOVEMBER 15 -19, 2008, (2008), vol. 38, XP008160443 [I] 1-14 * abstract *
	International search	[Y]US2005227929 (MASFERRER JAIME L [US]);
		[X]US2007129331 (GATELY STEPHEN [US], et al);
		[X]US2007197438 (REISER JOCHEN [US], et al)
	by applicant	US5525727
		US5618803
		US6110697
		US6407137
		US2003013176
		US2003082668
		US2003161830
		US2003224473
		US2004091951
		US2005118596
		US2005227300
		US2005288227
		US7119074
		US2007015183
		US2008300205
		- PRENDERGAST ET AL., SOC ETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, (2008), page 38
		- FRAY ET AL., "CANTAB battery: proposed utility in neurotoxicology.", NEUROTOXICOL TERATOL., (1996), vol. 18, no. 4, pages 499 - 504
		- DEHAENE ET AL., "Reward-dependent learning in neuronal networks for planning and decision making", BRAIN RES., (2000), vol. 126, page 21729
		- IVERSON ET AL., "Interpreting change on the WAIS-III/ WMS-III in clinical samples", ARCH CLIN NEUROPSYCHOL., (2001), vol. 16, no. 2, pages 183 - 91
		- WEAVER ET AL., "Mild memory impairment in healthy older adults is distinct from normal aging.", COGN., (2006), vol. 60, no. 2, pages 146 - 55
		- RICHON ET AL., METHODS ENZYMOL., (2004), vol. 376, pages 199 - 205
		- WEGENER ET AL., MOL GENETMETAB., (2003), vol. 80, no. 1-2, pages 138 - 47
		- ABUCHOWSKI; DAVIS, "Soluble Polymer-Enzyme Adducts", ABUCHOWSKI; DAVIS, HOCENBERG AND ROBERTS, Enzymes as Drugs, WILEY-INTERSCIENCE, (1981), pages 367 - 383
		- NEWMARK ET AL., J. APPL. BIOCHEM., (1982), vol. 4, pages 185 - 189
		- LANGER, SCIENCE, (1990), vol. 249, pages 1527 - 1533
		- WOOD MA; KAPLAN MP; PARK A; BLANCHARD EJ; OLIVEIRA AM; LOMBARDI TL; ABEL T, "Transgenic mice expressing a truncated form of CREB-binding protein (CBP) exhibit deficits in hippocampal synaptic plasticity and memory storage", LEARN MEM., (200503), vol. 12, no. 2, pages 111 - 9
		- CRUZ JC; TSENG H-C; GOLDMAN JA; SHIH H; TSAI L-H, "Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles", NEURON, (2003), vol. 40, pages 471 - 483
		- FISCHER A; SANANBENESI F; PANG PT; LU B; TSAI L-H, "Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory", NEURON, (2005), vol. 48, pages 825 - 838
		- FISCHER A; SANANBENESI F; WANG X; DOBBIN M; TSAI, L-H, "Recovery of learning and memory is associated with chromatin remodeling", NATURE, (2007), vol. 447, pages 178 - 182
		- MONFILS MH; COWANSAGE KK; KLANN E; LEDOUX JE, "Extinction-reconsolidation boundaries: key to persistent attenuation of fear memories", SCIENCE, (20090402), vol. 324, no. 5929, pages 951 - 5
		US20090508481

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p